This means that passive immunization with tau antibodies is actually a feasible therapeutic target and that the CSF degree of p-tau262/356 or with the microtubule binding area (MTBD) can serve as a valuable biomarker of tau pathology to watch tau therapeutics in clinical trials.1st, they examined this method on eighteen founded biosensor traces tha